Posted by Michael Wonder on 13 Dec 2015
FDA approves new oral therapy to treat ALK-positive lung cancer
11 December 2015 - The U.S. FDA today approved Alecensa (alectinib hydrochloride) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer whose disease has worsened after, or who could not tolerate treatment with Xalkori (crizotinib).
For more details, go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476926.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery
